News

The company placed 9.1 million shares with existing institutional shareholders at 225.00 pence per share. hVIVO will use the net proceeds of sale to progress PrEP-001 to Phase

Idarucizumab is indicated to reverse the anticoagulant effects of dabigatran etexilate during emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding. It binds specifically to

Sinclair said the sale creates an aesthetics firm, with high gross margins recorded in full year 2015. The company’s pro-forma net cash position of £82m will allow it

Fluad is the first adjuvanted seasonal influenza vaccine approved in the United States; it was specifically developed for the adult population aged 65 and older. Fluad is an

The expansion will provide additional office space and development services capacity to meet the growing demands of the pharmaceutical and biotechnology markets. The Wilmington site expansion will provide

The review of this application was conducted under the centralized licensing procedure as a therapeutic innovation, and is applicable in all 28 member states of the European Union,

Amgen believes this submission is the first adalimumab biosimilar application submitted to the FDA and represents Amgen’s first BLA submission using the 351(k) biosimilar pathway. Amgen executive vice

The approval was based on data the Phase III coBRIM study, which demonstrated that Cotellic plus Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live

The drug’s earlier indication was for the second-line treatment of NSCLC. The data supporting the expanded label was generated by the Phase 3 Profile 1014 study. The study